Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary
Veracyte bought another company called Convergent Genomics for cancer testing. When companies spend money on deals like this, watch if their new tools help them grow faster.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.